Keymed Biosciences Inc
Company Profile
Business description
Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. Its clinical-stage drug candidates include CM310, CM326, CM313, and CM336 among others. The company is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it generates a majority of its revenue from overseas markets and the rest from Mainland China.
Contact
No. 18 BioTown Middle Road
Building D2
Tianfu International BioTown, Chengdu
Sichuan610219
CHNT: +86 2888610620
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
1,625
Stocks News & Analysis
stocks
Which of the 3 giant AI IPOs should you buy?
stocks
Chart of the Week: Has gold reached bear market territory?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,916.20 | 16.50 | 0.19% |
| CAC 40 | 7,981.27 | 164.33 | 2.10% |
| DAX 40 | 23,298.89 | 618.85 | 2.73% |
| Dow JONES (US) | 46,565.74 | 224.23 | 0.48% |
| FTSE 100 | 10,364.79 | 188.34 | 1.85% |
| HKSE | 25,294.03 | 505.89 | 2.04% |
| NASDAQ | 21,840.95 | 250.32 | 1.16% |
| Nikkei 225 | 53,739.68 | 2,675.96 | 5.24% |
| NZX 50 Index | 12,942.95 | 117.08 | 0.91% |
| S&P 500 | 6,575.32 | 46.80 | 0.72% |
| S&P/ASX 200 | 8,705.80 | 20.80 | 0.24% |
| SSE Composite Index | 3,948.55 | 56.69 | 1.46% |